Literature DB >> 7259370

Lipoproteins, cardiovascular disease, and death. The Framingham study.

T Gordon, W B Kannel, W P Castelli, T R Dawber.   

Abstract

Based on six years of follow-up evaluations of the Framingham, Mass, men and women aged 49 to 82 years, it was found that a low-density lipoprotein (LDL) cholesterol concentration was associated with a low incidence of coronary heart disease (CHD) risk but with a statistically significant excess of stroke incidence in women and of deaths from non-CHD causes in both sexes. There was no suggestion that an elevated HDL cholesterol level was associated with an excess incidence of any of the cardiovascular end points considered or of death. An inverse relation of high-density lipoprotein (HDL) cholesterol level with CHD and its major consequences, CHD death and congestive heart failure, was observed. Triglyceride determinations seem to add little information respecting cardiovascular risk to that elicited from HDL and LDL cholesterol and other known cardiovascular risk factors. While the relation of HDL and LDL cholesterol with CHD is paralleled by findings from a variety of sources, the inverse relation of LDL cholesterol with stroke in women and with death from non-CHD causes requires additional confirmation and exploration.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7259370

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  86 in total

1.  ABC1: connecting yellow tonsils, neuropathy, and very low HDL.

Authors:  H H Hobbs; D J Rader
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

Review 2.  Impact of dyslipidaemia. Lessons from clinical trials.

Authors:  W V Brown
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 3.  Resource utilisation in the management of dyslipidaemia.

Authors:  T D Szucs
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

4.  Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis.

Authors:  H Bruunsgaard; P Skinhøj; A N Pedersen; M Schroll; B K Pedersen
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

5.  The triglyceride:high-density lipoprotein-cholesterol ratio and steno-occlusive disease in the intracranial arteries.

Authors:  Kyusik Kang; Kwangsub Lee; Sung-Hoon Chung
Journal:  J Thromb Thrombolysis       Date:  2011-07       Impact factor: 2.300

Review 6.  Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review.

Authors:  C Roger White; David W Garber; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2014-08-25       Impact factor: 5.922

Review 7.  Wnt signaling in cardiovascular disease: opportunities and challenges.

Authors:  Austin Gay; Dwight A Towler
Journal:  Curr Opin Lipidol       Date:  2017-10       Impact factor: 4.776

8.  Traditional and nontraditional cardiovascular risk factors in comorbid insomnia and sleep apnea.

Authors:  Faith S Luyster; Kevin E Kip; Daniel J Buysse; Aryan N Aiyer; Steven E Reis; Patrick J Strollo
Journal:  Sleep       Date:  2014-03-01       Impact factor: 5.849

9.  5 alpha-Cholest-8(14)-en-3 beta-ol-15-one, a potent inhibitor of sterol biosynthesis, lowers serum cholesterol and alters distributions of cholesterol in lipoproteins in baboons.

Authors:  G J Schroepfer; E J Parish; A Kisic; E M Jackson; C M Farley; G E Mott
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

10.  Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro.

Authors:  Tomoyuki Nishimoto; Yuichiro Amano; Ryuichi Tozawa; Eiichiro Ishikawa; Yoshimi Imura; Hidefumi Yukimasa; Yasuo Sugiyama
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.